Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
Rhea-AI Summary
Vanda Pharmaceuticals (Nasdaq: VNDA) will participate in the J.P. Morgan Healthcare Conference in San Francisco on January 15, 2026. A corporate presentation is scheduled for 9:00 a.m. PT / 12:00 p.m. ET. The presentation will be accessible live via Vanda's website under the Investors > Recent Events section.
Investors are advised to visit the conference website at least 15 minutes early to register and install any required software. A link to the archived presentation will be available on Vanda's website for approximately 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – VNDA
In the Dec 12 session, VNDA declined 5.61%, reflecting a notable negative market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 04 | Regulatory update | Positive | -0.8% | FDA lifted partial clinical hold on tradipitant protocol VP-VLY-686-3403. |
| Nov 28 | Regulatory update | Positive | +1.1% | FDA expedited re-review and confirmed tradipitant PDUFA 12/30/2025. |
| Nov 17 | Clinical data | Positive | +1.1% | Tradipitant reduced GLP-1–induced vomiting with significant p-values and good safety. |
| Nov 05 | Conference participation | Neutral | -0.7% | Announcement of corporate presentation at Stifel 2025 Healthcare Conference. |
| Oct 29 | Earnings and pipeline | Negative | -3.0% | Q3 loss, lowered 2025 guidance, and multiple upcoming PDUFA and BLA milestones. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent price reactions show positive alignment with favorable clinical and regulatory updates, while neutral conference announcements and some positive FDA developments have seen weaker or negative immediate responses.
Over the last few months, VNDA reported several key milestones. On Oct 29, 2025, Q3 results showed higher sales but a $22.6M net loss and lowered 2025 guidance. Subsequent news included participation in the Stifel 2025 Healthcare Conference on Nov 12, 2025, positive tradipitant data in GLP-1–induced nausea, and regulatory updates with a Dec 30, 2025 PDUFA date. On Dec 4, 2025, the FDA lifted a partial tradipitant hold. Today’s J.P. Morgan conference participation continues this pattern of active investor and scientific engagement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The corporate presentation given at the J.P. Morgan Healthcare Conference may be accessed live on Vanda's corporate website, www.vandapharma.com. Investors should click on the Investors tab and follow the link under Recent Events. Investors are advised to go to the conference website at least 15 minutes early to register, download, and install any necessary software or presentations. A link to the archived conference will be available on Vanda's website for a period of approximately 30 days.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-participation-in-the-jp-morgan-healthcare-conference-302639678.html
SOURCE Vanda Pharmaceuticals Inc.